Prenatal molecular diagnosis and carrier detection of Duchenne muscular dystrophy in Korea

Min Ji Kang¹,², Moon-Woo Seong¹, Sung Im Cho¹, Joong Shin Park¹, Jong Kwan Jun¹,², and Sung Sup Park¹

¹Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
²Department of Obstetrics and Gynecology, Gimcheon Jeil Hospital, Gimcheon, Korea

Purpose: Duchenne muscular dystrophy (DMD) is the most common lethal muscular dystrophy and is caused by the genetic variants of DMD gene. Because DMD is X-linked recessive and shows familial aggregates, prenatal diagnosis is an important role in the management of DMD family. We present our experience of prenatal molecular diagnosis and carrier detection based on multiplex polymerase chain reaction (PCR), multiplex ligation-dependent probe amplification (MLPA), and linkage analysis.

Materials and Methods: During study period, 34 cases of prenatal diagnosis and 21 cases of carrier detection were performed at the Seoul National University Hospital. Multiplex PCR and MLPA was used to detect the exon deletions or duplications. When the DMD pathogenic variant in the affected males is unknown and no DMD pathogenic variant is detected in at-risk females, linkage analysis was used.

Results: The prenatal molecular diagnosis was offered to 34 fetuses. Twenty-five fetuses were male and 6 fetuses (24.0%) were affected. Remaining cases had no pathogenic mutation. We had 24 (80.0%) cases of known proband results; exon deletion mutation in 19 (79.2%) cases and duplication in 5 (20.8%) cases. Linkage analysis was performed in 4 cases in which 2 cases (50.0%) were found to be affected. In the carrier testing, among 21 cases including 15 cases of mother and 6 cases of female relative, 9 (42.9%) cases showed positive results and 12 (57.1%) cases showed negative results.

Conclusion: Prenatal molecular diagnosis and carrier detection of DMD are effective and feasible. They are useful in genetic counseling for DMD families.

Key words: Prenatal diagnosis, Muscular dystrophy, Duchenne, Multiplex polymerase chain reaction, Multiplex ligation-dependent probe amplification, Linkage analysis.

Introduction

Duchenne muscular dystrophy (DMD) is one of neuromuscular diseases characterized by progressive muscular weakness and degeneration of skeletal muscle [1]. The onset of DMD symptoms is observed ages between 2 and 3. Usually, affected boys have difficulty in motor development, approximately half of affected fail to walk until 18 months of age. It is the most...
common X-linked recessive fatal disease occurring in 1 in 3,500 newborns, and results from pathogenic variants in the dystrophin gene encoding the dystrophin protein [2,3]. The dystrophin gene is found in the short arm of the X chromosome (X-p21.2) [4]. Its 11.3 kb long coding sequence embraces 79 exons and 7 unique promoters and introns which comprise 99.5% of the DMD gene [5].

Prenatal diagnosis for DMD was first introduced in 1984 [6].

Prenatal tests for DMD are performed for a male fetus whereas no testing is mandate for female fetuses [7]. Traditional genetic diagnosis for DMD detects large mutations at first and smaller mutations subsequently by applying two or more analytical methods. Conservative prenatal diagnosis detects any known familial mutation in male fetal DNA by chorionic villus sampling or amniocentesis [8]. The same approach can be applied to detect the mutation of the proband and female carriers [7].

Table 1. Prenatal diagnosis of 34 fetuses in DMD high-risk families

| No. | Date   | Sample | Tests           | Proband | Carrier status | Sex | Results |
|-----|--------|--------|-----------------|---------|----------------|-----|---------|
| 1   | 1997.9 | AF     | Multiplex PCR   | None    | M              | M   | Normal  |
| 2   | 2000.9 | AF     | Multiplex PCR   | None    | Aunt           | F   |         |
| 3   | 2002.1 | AF     | Multiplex PCR   | 50 del  | Mother         | M   | DMD     |
| 4   | 2004.1 | AF     | Multiplex PCR   | 49-52 del | Mother    | M   | Normal  |
| 5   | 2004.3 | CVS    | Multiplex PCR   | 45-52 del | Aunt    | M   | DMD     |
| 6   | 2004.7 | CVS    | Multiplex PCR   | None    |               | F   |         |
| 7   | 2004.9 | AF     | Multiplex PCR   | 48 del  | Mother         | M   | Normal  |
| 8   | 2005.1 | AF     | Multiplex PCR   | None    | Sister         | M   | Normal  |
| 9   | 2005.1 | AF     | Multiplex PCR   | 47-52 del | Mother    | M   | Normal  |
| 10  | 2005.1 | AF     | Multiplex PCR   | None    | Aunt           | M   | Normal  |
| 11  | 2005.3 | CVS    | Multiplex PCR   | 45-52 del | Aunt    | M   | Normal  |
| 12  | 2005.5 | AF     | Multiplex PCR   | 6-8 del | Mother         | F   |         |
| 13  | 2005.8 | AF     | Multiplex PCR   | 46-47 del | Mother    | M   | Normal  |
| 14  | 2006.2 | AF     | MLPA+Multiplex PCR | 45-52dup | Aunt | F   |         |
| 15  | 2006.5 | AF     | MLPA+Multiplex PCR | 45-54 del | Mother    | M   | Normal  |
| 16  | 2006.9 | AF     | MLPA+Multiplex PCR | 46-61 dup | Sister    | M   | Normal  |
| 17  | 2007.1 | AF     | MLPA+Multiplex PCR | None    | Sister         | M   | Normal  |
| 18  | 2007.2 | AF     | MLPA+Multiplex PCR | 2 dup   | Mother         | M   | Normal  |
| 19  | 2007.9 | AF     | MLPA+Multiplex PCR | 54 dup   | Mother         | M   | Normal  |
| 20  | 2007.9 | AF     | MLPA+Multiplex PCR | 46-48 del | Mother    | M   | Normal  |
| 21  | 2007.11| AF     | MLPA+Multiplex PCR | 45-50 del | Mother +     | M   | DMD     |
| 22  | 2007.12| AF     | MLPA+Multiplex PCR | 48-52 del | Mother +     | F   |         |
| 23  | 2008.3 | AF     | MLPA+Multiplex PCR | 12-17 del | Mother    | M   | Normal  |
| 24  | 2008.3 | AF     | MLPA+Multiplex PCR | 8-26 del | Mother         | F   |         |
| 25  | 2008.5 | AF     | MLPA+Multiplex PCR | 41-43 del | Mother         | F   |         |
| 26  | 2008.6 | AF     | MLPA+Multiplex PCR | 46-61 dup | Sister    | M   | Normal  |
| 27  | 2008.7 | AF     | MLPA+Multiplex PCR | 44 del   | Mother +     | M   | Normal  |
| 28  | 2008.9 | AF     | MLPA+Multiplex PCR | 3-44 del | Mother         | M   | DMD     |
| 29  | 2009.1 | AF     | MLPA+Multiplex PCR | 3-17 del | Aunt +        | M   | Normal  |
| 30  | 2009.9 | CVS    | MLPA+Multiplex PCR | 48-52 del | Mother +     | M   | Normal  |
| 31  | 2007.7 | AF     | Linkage analysis | Mother   |               | DMD |         |
| 32  | 2007.9 | AF     | Linkage analysis | Aunt     |               | DMD |         |
| 33  | 2007.11| AF     | Linkage analysis | Mother   |               | Normal |         |
| 34  | 2008.12| AF     | Linkage analysis | Sister   |               | Normal |         |

DMD, Duchenne muscular dystrophy; AF, amniotic fluid; PCR, polymerase chain reaction; M, male; F, female; CVS, chorionic villus sampling; MLPA, multiplex ligation-dependent probe amplification.
If the familial mutation is not observed, haplotyping is another method for prenatal diagnosis [9].

Since the locus of the DMD gene identified in 1986 by independent experimental methods [10,11], clinicians have heavily concentrated on the molecular diagnosis of DMD. Definite treatment is not available. Therapies under investigation; pregnancy management for female carriers; genetic counseling for risk to family members and family planning; and prenatal testing and preimplantation genetic diagnosis (PGD) are all dependent on the precise molecular diagnosis of the disorders.

Many diagnostic testing procedures are employed for DMD mutation tests including multiplex polymerase chain reaction (PCR), multiplex ligation-dependent probe amplification (MLPA), array comparative genome hybridization (CGH), PCR-based Sanger sequencing, and others [12].

Some laboratories still use Multiplex PCR to identify common dystrophin deletions due to its convenience and cost-efficiency to perform [12]. Since the introduction of MLPA by Schouten in 2002, there has been a substantial increase in detection rate of dystrophin mutations as the majority of mutations developing DMD are intragenic deletions or duplications representing 65% and 5% of total cases, respectively [5].

The aim of this study is to show our clinical experience in prenatal diagnosis and carrier detection of DMD using molecular biologic techniques.

**Materials and Methods**

1. **Study subjects**

   The prenatal diagnosis data of 34 at-risk pregnancies in DMD families referred to the department of obstetrics and gynecology in Seoul National University Hospital from September 1997 to January 2010 were retrospectively reviewed. Peripheral blood was collected from 24 male probands clinically diagnosed with DMD and 21 corresponding female relatives for carrier tests. This study was approved by the ethics committee of Seoul National University Hospital. Written informed consent was obtained from the patients or their guardians.

2. **Specimens**

   For the pregnant women, chorionic villi biopsy was performed at 11 to 14 week gestation, 10-20 mL of amniotic fluid was collected via amniocentesis at 14 to 18 week gestation to obtain genomic DNA from fetus. Chorionic villi and amniocyte culture was done for prenatal genetic diagnosis. A total of 2 mL of peripheral blood was collected from patients to obtain genomic DNA for proband and carrier tests.

3. **Mutation analysis**

   Genomic DNA was extracted from chorionic villi, amniocytes, and the patients’ peripheral blood using Gentra PureGene DNA Isolation Kits (Gentra Systems Inc., Minneapolis, MN, USA). Multiplex PCR was used to detect exon deletion in 26 sites. Exon deletion or duplication of dystrophin was screened using MLPA. MLPA was performed using the SALSA P034 DMD mix 1 Kit and P035 DMD mix 2 Kit (MRC Holland, Amsterdam, The Netherlands). PCR products were analyzed on an ABI 3130 analyzer using Genemarker v1.51 (Softgenetics, State College, PA, USA). Peak heights were normalized, and a deletion or duplication was suspected when a normalized peak ratio was under 0.75 or above 1.30. Linkage analysis was done using 14 different short tandem markers spanning the DMD gene, including DXS1049, DXS1242, and etc. PCR-restriction fragment length polymorphism, and detection of ZF gene in X chromosome/ZF gene in Y chromosome were used to identify sex of fetus.

**Results**

The prenatal molecular diagnosis was offered to 34 fetuses...
To detect the exon deletion or duplication, multiplex PCR was used (Fig. 1) and after 2005, MLPA was introduced for screening (Fig. 2). Twenty-five fetuses were male and 6 fetuses (24.0%) were affected. We had 24 (80.0%) cases of known proband results; exon deletion mutation in 19 (79.2%) cases and duplication in 5 (20.8%) cases (Fig. 3). Remaining cases had no pathogenic mutation. However, the prenatal tests could not be performed if no patients survived in their households. When the fetus was a male (Case no. 1, 8, 10, and 17), a possible test only showed that there was no known deletion/duplication of the DMD gene exon. In this context, DMD/BMD due to point mutation cannot be excluded. Linkage analysis was performed in 4 cases which resulted in 2 affected cases (50.0%) (Fig. 4). In the carrier testing, among 21 cases including 15 cases of mother and 6 cases of female relative, 9 (42.9%) cases showed positive results and 12 (57.1%) cases showed negative results (Fig. 5). Of 12 cases which showed negative results in the carrier testing, 7 (58.3%) cases were male cases and all of these cases were negative in prenatal diagnosis.

![Fig. 3. Cases analyzed by multiplex polymerase chain reaction and multiplex ligation-dependent probe amplification.](image)

| Marker     | Location | Mother | Fetus | Proband | Father |
|------------|----------|--------|-------|---------|--------|
| DXS048     | 174/176  | 195    | 195   | 195     | 195    |
| DYSIII Promotor | 67/85 | 85     | 85    | 67      |        |
| DXS1243    | 206/224  | 224    | 224   | 206     |        |
| DXS1243    | 207/198  | 207    | 207   | 205     |        |
| DXS1243    | 185/185  | 185    | 185   | 195     |        |
| DXS1243    | 173/177  | 177    | 177   | 169     |        |
| DXS1243    | 240/244  | 244    | 244   | 240     |        |
| DXS1243    | 145/145  | 145    | 145   | 147     |        |
| DXS1243    | 211/215  | 215    | 215   | 219     |        |
| DXS1243    | 132/132  | 132    | 132   | 132     |        |
| DXS1243    | 68/72    | 68     | 68    | 68      |        |
| DXS1243    | 128/128  | 128    | 128   | 128     |        |

![Fig. 4. Linkage analysis.](image)
Discussion

This study showed current status of prenatal molecular diagnosis and carrier detection of DMD in Korean. As a result of the study, affected male fetus accounted for 6 of 25 (24.0%) male fetuses, which is somewhat lower compared to 34 of 91 (37.4%) male fetuses in the previous study [13]. This may be due to the variance in patient group and race, the percentage of patients without proband results, and the diagnostic method used for prenatal diagnosis.

Among 30 fetuses analyzed by Multiplex PCR and MLPA, the percentage of patients without proband results was 6 of 30 (20.0%) fetuses. In particular, there was not much genetic information about probands in the initial cases during study periods, because genetic counselling for DMD in the early stages of the study was relatively uncommon compared to the present, and there might be possibilities of early death of proband prior to molecular diagnosis. For another reason, it is considered that muscle biopsies were common in the early 2000s accounting for more than two thirds among various diagnostic tools for DMD.

When analyzed chronologically over 10 years, the rate of muscle biopsies in total diagnosed cases has gradually fallen from 96.8% in 1990s to 19.3% in 2010s as molecular diagnosis techniques improved [14]. Because of the improvement of molecular diagnosis techniques, most DMD patients are diagnosed genetically without muscle biopsies recently.

As MLPA was first described by Schouten et al. [15] in 2002, multiplex PCR was used for detection of deletions in dystrophin gene in this study without MLPA. Multiplex PCR is a method to test the presence or absence of exon deletion of the DMD gene dystrophin; Xp21.2 and the test confirmed the exon deletion of 26 sites. About two thirds of DMD patients are caused by exon deletion and multiplex PCR can diagnose more than 99% of exon deletion patients. Therefore, some laboratories still use this method because of its convenience and cost-efficiency to perform [12].

Multiplex PCR is used to identify deletions at a hemizygous locus but it is impossible to completely describe deletions because of its limitation to cover the whole gene and incapacity to detect duplications or female carriers. These are the critical drawbacks of Multiplex PCR [16]. It also has difficulties to differentiate whether the deletion detected is in-frame or out-of-frame, and to apply exon skipping therapy consequently. Additionally, it is impossible to determine boundaries of the deletion [12].

In present study, no duplication was found in the mutation of the proband when multiplex PCR was used but the duplication was found after MLPA introduction. In 24 total cases in which proband results exist, 19 (79.2%) cases were exon deletion mutation and 5 (20.8%) cases were duplication mutation. This rate is similar to the results of previous studies reporting mutation spectrum in the dystrophin gene of 507 Korean boys [14].

When the DMD gene variant observed in an affected male,
carrier diagnosis could be applicable to the mother and female relatives at risk, who are heterozygotes for the pathogenic gene variant. In this study, carrier test was performed in 21 cases except 3 cases among 24 cases in which DMD gene variants of affected males were identified. Carrier test results provide information in deciding whether to perform a prenatal diagnosis. Also these results are clinically important as abnormal cardiac monitoring is essential for asymptomatic heterozygous females and a cardiac evaluation should be considered prior to conception or during pregnancy [12].

In the present cohort, the results revealed that 9 of 21 (42.9%) mothers were carriers. Of the 21 cases with both proband and carrier results, 12 of 21 (57.1%) were carrier negative. The de novo mutation of the DMD gene and germline mosaicism can be considered for this discrepancy. If the mother was not a carrier, her son with DMD mostly had a de novo mutation. However, germline mosaicism in DMD should not be ignored as described in the 1980s, conferring a recurrence risk for the next son [17,18].

Although 7 male fetuses of carrier negative patients were all negative in the prenatal diagnosis and the 7 male fetuses who were born healthily in this study, the possibility of germline mosaicism cannot be completely excluded. Wang et al. reported 3 cases of germline mosaicism in 50 mothers with no pathogenic mutations [19]. Furthermore, Bermúdez-López et al. [20] verified that germline mosaicism deletions have been reported in at least 11.6% of families of DMD patients, suggesting that mosaicism should be considered in the genetic counseling. In our center, prenatal diagnosis was suggested to at-risk pregnant women in DMD families regardless of their carrier status.

Because recent prenatal diagnosis is offered based upon the presence of an affected boy, it is insufficient to detect fetuses with de novo mutations. De novo mutations represent approximately one third of DMD patients. This issue can be resolved by offering prenatal diagnostic test for the dystrophin gene to every pregnant woman. Advancing in non invasive prenatal diagnosis or during pregnancy [12].

In conclusion, this study showed prenatal diagnosis and carrier detection using multiplex PCR, MLPA, and linkage analysis were effective measures to detect DMD.

Acknowledgements

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI08C0537).

References

1. Emery AE. The muscular dystrophies. Lancet 2002;359:687-95.
2. Ellis JA, Vroom E, Muntoni F. 195th ENMC International workshop: newborn screening for Duchenne muscular dystrophy 14–16th December, 2012, Naarden, The Netherlands. Neuromuscul Disord 2013;23:682-9.
3. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28.
4. Murray JM, Davies KE, Harper PS, Meredith L, Mueller CR, Williamson R. Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. Nature 1982;300:69-71.
5. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731-40.
6. Bakker E, Hofker MH, Goor N, Mandel JL, Wrogemann K, Davies KE, et al. Prenatal diagnosis and carrier detection of Duchenne muscular
dystrophy with closely linked RFLPs. Lancet 1985;1:655-8.
7. Abbs S, Tuffery-Giraud S, Bakker E, Ferlini A, Sejersen T, Mueller CR. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscul Disord 2010;20:422-7.
8. Xu Y, Li X, Ge HJ, Xiao B, Zhang YY, Ying XM, et al. Haplotype-based approach for noninvasive prenatal tests of Duchenne muscular dystrophy using cell-free fetal DNA in maternal plasma. Genet Med 2015;17:889-96.
9. Helderman-van den Enden AT, Madan K, Breuning MH, van der Hout AH, Bakker E, de Die-Smulders CE, et al. An urgent need for a change in policy revealed by a study on prenatal testing for Duchenne muscular dystrophy. Eur J Hum Genet 2013;21:21-6.
10. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986;323:646-50.
11. Kunkel LM, Hejtmancik JF, Caskey CT, Speer A, Monaco AP, Middlesworth W, et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 1986;322:73-7.
12. Aartsma-Rus A, Ginjaaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 2016;53:145-51.
13. Wang H, Xu Y, Liu X, Wang L, Jiang W, Xiao B, et al. Prenatal diagnosis of Duchenne muscular dystrophy in 131 Chinese families with dystrophinopathy. Prenat Diagn 2017;37:356-64.
14. Cho A, Seong MW, Lim BC, Lee HJ, Byeon JH, Kim SS, et al. Consecutive analysis of mutation spectrum in the dystrophin gene of 507 Korean boys with Duchenne/Becker muscular dystrophy in a single center. Muscle Nerve 2017;55:727-34.
15. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
16. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-89.
17. Bakker E, Van Broeckhoven C, Bonten EJ, van de Vooren MJ, Veenema H, Van Hul W, et al. Germline mosaicism and Duchenne muscular dystrophy mutations. Nature 1987;329:554-6.
18. Darras BT, Francke U. A partial deletion of the muscular dystrophy gene transmitted twice by an unaffected male. Nature 1987;329:556-8.
19. Wang Y, Yang Y, Liu J, Chen XC, Liu X, Wang CZ, et al. Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. Mol Genet Genomics 2014;289:1013-21.
20. Bermúdez-López C, García-de Teresa B, González-del Angel A, Alcántara-Ortigoza MA. Germline mosaicism in a sample of families with Duchenne/Becker muscular dystrophy with partial deletions in the DMD gene. Genet Test Mol Biomarkers 2014;18:93-7.
21. Jang SS, Lim BC, Yoo SK, Shin JY, Kim KJ, Seo JS, et al. Targeted linked-read sequencing for direct haplotype phasing of maternal DMD alleles: a practical and reliable method for noninvasive prenatal diagnosis. Sci Rep 2018;8:8678.
22. Prior TW, Bartolo C, Papp AC, Snyder PJ, Sedra MS, Burghes AH, et al. Dystrophin expression in a Duchenne muscular dystrophy patient with a frame shift deletion. Neurology 1997;48:486-8.